Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Mologen initiates lung cancer trial of MGN-1703 in Belgium

March 27, 2014

Siltuximab receives positive CHMP opinion supporting approval in multicentric Castleman's disease

March 25, 2014

ArevaMed presents phase I data for 212Pb-TCMC-trastuzumab

March 24, 2014

Phase III trial of GSK's MAGE-A3 immunotherapeutic in NSCLC misses first co-primary endpoints

March 21, 2014

Advaxis and UCSF to assess cancer immunotherapy constructs

March 19, 2014

Igenica Biotherapeutics doses first patient in phase I study of IGN-523

March 19, 2014

Japanese approval for Poteligeo in PTCL and CTCL

March 17, 2014

U.S. researchers prepare new MAbs for diagnostic and treatment of cancer

March 17, 2014

Peregrine Pharmaceuticals' PS-targeted programs supported by recent preclinical data

March 14, 2014

Fate Therapeutics begins phase II trial of ProHema for hematologic malignancies

March 13, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...